| Project/Area Number |
20591882
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Oita University |
|---|
Principal Investigator |
MIMATA Hiromitsu Oita University, 医学部, 教授 (60219714)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SATO Fuminori 大分大学, 医学部, 准教授 (30305049)
HIRATA Yuji 大分大学, 医学部, 助教 (30295183)
SUMINO YASUHIRO 大分大学, 医学部, 助教 (30325716)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2010: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2009: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2008: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | 尿失禁 / 外尿道括約筋 / 骨格筋幹細胞 / サイトカイン / シグナル伝達 / アポトーシス / TGF-β / 腹圧性尿失禁 / 横紋筋幹細胞 / Mostatin / Follistatin / TNF-α / 骨格筋衛星細胞 / 高齢者 / 炎症性サイトカイン |
|---|
| Research Abstract |
Fragility of urethral rhabdosphincter is one of the causes for urinary stress incontinence following prostatectomy and in the elderly. To develop new treatment modality of urinary incontinence by regeneration of urethral rhabdosphincter, human satellite cells of urethral rhabdosphincter were separated and cultured to explore the effects of variety of cytokines on them and the signal transduction.
TNF-αdose-dependently suppressed the growth of satellite cells of human urethral rhabdosphincter and induced apoptosis in part, and anti- TNF-αdrugs inhibited these effects. Myostatin, skeletal muscle-specific growth inhibiting factor, was expressed on mRNA and protein levels in satellite cells of human urethral rhabdosphincter. Myostatin suppressed their growth dose-dependently, and its inhibitor, Follistatin, reversed its inhibitory effect.
Regeneration of human urethral rhabdosphincter may be possible with anti-TNF-αdrugs and Myostatin inhibitors and prove a novel therapeutic modality for urinary incontinence.
|
